5th World Congress of the International Academy of Oral Oncology (IAOO)

Pannone, Giuseppe; Ninivaggi, Rossella; Cagiano, Simona; Petruzzi, Massimo; Rosalia, Leonardi; Angela, Santoro; Campisi, Giuseppina; Rodolico, Vito; Colella, Giuseppe; Bufo, Pantaleo

doi:10.1002/hed.24138

Cited by 2 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies included in this systematic review were prospective cohorts, 25,32,36,38,[40][41][42][43][46][47][48][49][50][51][52]55 RCTs, 37,45,53 or CS studies. 22,39,44,54…”

Section: Methodsmentioning

confidence: 99%

“…All the 81 manuscripts identified as eligible based on the abstracts and titles were searched for full-text and analyzed for inclusion independently by three authors. Twenty-three manuscripts were relevant for inclusion in qualitative analysis (Table S2 shows a list of included studies with main characteristics 22,25,32,[36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55] ). Main reasons for exclusion of those 58 references were that data were collected retrospectively (n = 10), subjective methods or ill/not defined objective measurements (n = 38), different intervention that is, brachytherapy, proton therapy (n = 2), not HNC (n = 1), no trismus outcome (n = 5), conference/abstract (n = 1), and a duplicate (n = 1).…”

Section: Qualitative Analysismentioning

confidence: 99%

“…Participants with HNC undergoing primary therapy. The number of participants ranged from 22 41,42 to 641. 51 studies were multi-center.…”

Section: Populationmentioning

confidence: 99%

“…The majority included a combination of surgery, RT, and chemotherapy. 22,[36][37][38][39][40]43,45,[47][48][49][50][51]54,55 Few included patients treated with definitive RT +/− chemotherapy without surgery 25,32,41,42,44,52,53 and only one reported RT alone (hyperfractionated). 46 Many did not clearly define the type or dose of RT or included patients treated with a mixture of types and doses of RT.…”

Section: Interventionmentioning

confidence: 99%

“…Of the 23 articles included in this review, 13 (56.5%) were prospective cohorts with good follow-up (level of evidence 1b), 3 (13.0%) of the included articles were RCT's with level of evidence 1b, 2 of the cohorts (8.7%) had poor follow-up (<80%) 41,43 with level of evidence 2b, and 5 studies (21.7%) were CS studies with level of evidence 3b (Table 1).…”

Section: Summary Of Quality Of the Evidencementioning

confidence: 99%

See 4 more Smart Citations

Prevalence of trismus in patients with head and neck cancer: A systematic review with meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Background The purpose of this systematic review and meta‐analysis was to determine the prevalence of trismus in patients with head and neck cancer. Methods Four electronic databases were searched: Cochrane Library, MEDLINE, EMBASE, and Web of Science up to April 2018. Level of evidence was assessed based on Oxford Centre for Evidence‐based Medicine. Publications were restricted to prospective cohort studies (n = 15), randomized clinical trials (n = 3), and cross‐sectional studies (n = 5) reporting on trismus as mouth maximum opening less than or equal to 35 mm in the English language. Results A total of 636 abstracts were reviewed for inclusion. Twenty‐three studies were included in qualitative analysis and 15 studies in meta‐analysis. The results included 2786 patients with head and neck cancer treated with surgery, radiotherapy, and/or chemotherapy either alone or in combination. Based on meta‐analyses, the weighted average prevalence of trismus increased from 17.3% at baseline (95% confidence interval [CI], 10.8%‐26.5%) to a peak of 44.1% at 6 months (95% CI, 36.7%‐51.8%) and decreased to 32.1% at 12 months (95% CI, 27.2%‐37.4%) and continued in average 32.6% at 3‐10 years (95% CI, 22.0%‐45.3%). Conclusions Having a primary site of the oral cavity or oropharynx was associated with a higher risk for developing trismus based on individual studies. Prospective cohort studies or randomized controlled trials with multiple objective trismus measurements, evaluation of disease characteristics, and treatment variables are needed to further investigate the prevalence of trismus secondary to head and neck cancer treatment.

show abstract

“…The studies included in this systematic review were prospective cohorts, 25,32,36,38,[40][41][42][43][46][47][48][49][50][51][52]55 RCTs, 37,45,53 or CS studies. 22,39,44,54…”

Section: Methodsmentioning

confidence: 99%